Open-Source Alzheimer's Research

Scientists Reversed Alzheimer's in Mice. We're Building the Bridge.

The gap between a mouse study and a human therapy isn't just biology — it's tooling. We build the open-source AI infrastructure to close that gap. Self-funded. Not-for-profit. Radically open.

Fund the Bridge Read the Science

"My mother died from Alzheimer's. My sister was diagnosed 18 months ago. This isn't a research interest — it's a race against the clock I can hear ticking in every phone call home."

David Scott Lewis

Founder, The Reversal Initiative

55M

People living with dementia worldwide

Open AI tools for Alzheimer's drug design

10+

Druggable targets in the NAD+ pathway

37+

Pipeline modules built and validated

What We Build

Three Pillars of Open Drug Discovery

Every tool we build is open-source, peer-reviewed, and designed so any lab on Earth can use it — not just those with billion-dollar budgets.

SCREEN Targets

AI-driven target identification across the NAD+ biosynthesis pathway. Our models evaluate binding affinity, selectivity, and blood-brain barrier penetration to prioritize the most promising intervention points.

BUILD Molecules

Generative chemistry pipelines that design novel neuroprotective compounds. Each candidate is optimized for drug-likeness, synthesizability, and predicted efficacy against validated Alzheimer's mechanisms.

VERIFY Safety

Multi-scale toxicity prediction before any compound reaches a living cell. Off-target binding, hepatotoxicity, cardiotoxicity, and mutagenicity are all flagged computationally — reducing animal testing and accelerating timelines.

Peer-Reviewed Breakthrough

P7C3-A20 Reverses Alzheimer's Pathology in Mice

Published in Cell Reports Medicine (2025), researchers demonstrated that the P7C3-A20 compound — an NAD+ pathway activator — reversed cognitive decline, reduced amyloid plaques, and restored synaptic function in Alzheimer's mouse models. This is the foundational biology our AI tools are built to accelerate.

DOI: 10.1016/j.xcrm.2025.102535

Your Impact

What Your Contribution Builds

Every euro funds tools, not overhead. We publish cost breakdowns quarterly.

€25

Supporter

Funds one GPU-hour of molecular docking simulation — enough to screen 1,000 compounds against a validated Alzheimer's target.

1,000 compounds screened

€100

Accelerator

Runs a complete binding-affinity prediction cycle on our top 50 candidate molecules, including ADMET profiling.

Full ADMET on 50 leads

€500

Catalyst

Sponsors a complete target-to-lead sprint: target validation, hit generation, lead optimization, and toxicity filtering.

One complete sprint

€5,000

Pioneer

Funds an entire pipeline module release — from architecture to peer review — that becomes a permanent, open-source public good.

Permanent open-source module

Traction

Where This Work Stands

AAAI-26 Oral

Accepted for oral presentation at the premier AI conference

NeurIPS Workshop

AI for Drug Discovery workshop with peer review

Stanford Collab

Methodology validated by Stanford computational biology group

2 Drug Programs

Tools actively used in commercial drug discovery pipelines

Someone is diagnosed every 3 seconds

Every Euro Builds Tools That Outlast Any Single Trial

Drugs fail. Tools compound. Your contribution doesn't fund one experiment — it builds infrastructure that every Alzheimer's researcher on Earth can use, forever.

Donate Now

Tax-deductible in applicable jurisdictions · 100% funds tools, not salaries